drugset / Trial / NCT02658084
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
Non-randomizedCrossoverOpen-labelTreatment
Summary
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
Timeline
- Start
- 2017-04-12
- Primary completion
- 2018-10-11
- Completion
- 2018-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |
| Subject | Vinorelbine | Small molecule | 22.5 mg/m2 | Intravenous |